文献速递外周动脉疾病

下肢动脉疾病患者细胞外基质相关生物标志物的评估

Assessment of extracellular matrix-related biomarkers in patients with lower extremity artery disease.
PubMed 文献 · J Vasc Surg · 2018-03-31

研究通过蛋白质组学分析病变动脉,并在195例连续下肢动脉疾病患者中检测细胞外基质蛋白新表位片段。结果发现多功能蛋白聚糖和IV型胶原片段可区分轻中度症状(间歇性跛行,Fontaine I-II)与重度下肢动脉疾病(严重肢体缺血,Fontaine III-IV)。作者提出这些无创候选生物标志物可能具有临床实用性。

要点

  • 病变动脉蛋白质组显示14/81种蛋白差异表达,多与细胞外基质相关。
  • 血液多功能蛋白聚糖和IV型胶原片段可区分Fontaine I-II与III-IV患者。
  • 作者提出这些无创候选生物标志物可能在整个下肢动脉疾病谱中具有临床实用性。

核心结论

  • 作者提出具有临床实用潜力的无创候选生物标志物,可覆盖下肢动脉疾病谱。

研究设计与样本

  • 对接受腹股沟下肢体血运重建患者的病变动脉进行液相色谱串联质谱非靶向蛋白质组学分析。
  • 采用特异性酶联免疫吸附试验检测195例连续下肢动脉疾病患者血液中的细胞外基质蛋白新表位片段。

主要发现

  • 组织学和蛋白质组学分析证实病变动脉存在结构紊乱。
  • 81种蛋白中14种在病变动脉与健康组织间差异表达,多数与细胞外基质成分相关。
  • 多变量分析表明重度下肢动脉疾病患者具有特定蛋白质组。
  • 血液中多功能蛋白聚糖和IV型胶原片段单独或联合可区分轻中度症状(间歇性跛行,Fontaine I-II)与重度下肢动脉疾病(严重肢体缺血,Fontaine III-IV)患者。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The prevalence of lower extremity artery disease (LEAD) is high (20%-25%) in the population older than 65 years, but patients are seldom identified until the disease is advanced. Circulating markers of disease activity might provide patients with a key opportunity for timely treatment. We tested the hypothesis that measuring blood-specific fragments generated during degradation of the extracellular matrix (ECM) could provide further insight into the pathophysiologic mechanism of arterial remodeling. METHODS: The protein profile of diseased arteries from patients undergoing infrainguinal limb revascularization was assessed by a liquid chromatography and tandem mass spectrometry, nontargeted proteomic approach. The information retrieved was the basis for measurement of neoepitope fragments of ECM proteins in the blood of 195 consecutive patients with LEAD by specific enzyme-linked immunosorbent assays. RESULTS: Histologic and proteomic analyses confirmed the structural disorganization of affected arteries. Fourteen of 81 proteins were identified as differentially expressed in diseased arteries with respect to healthy tissues. Most of them were related to ECM components, and the difference in expression was used in multivariate analyses to establish that severe arterial lesions in LEAD patients have a specific proteome. Analysis of neoepitope fragments in blood revealed that fragments of versican and collagen type IV, alone or in combination, segregated patients with mild to moderate symptoms (intermittent claudication, Fontaine I-II) from those with severe LEAD (critical limb ischemia, Fontaine III-IV). CONCLUSIONS: We propose noninvasive candidate biomarkers with the ability to be clinically useful across the LEAD spectrum.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Hernández-Aguilera A, Nielsen SH, Bonache C, et al. Assessment of extracellular matrix-related biomarkers in patients with lower extremity artery disease. J Vasc Surg. 2018. PMID: 29615349. doi:10.1016/j.jvs.2017.12.071

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。